Epoetin delta as an antifibrotic agent in the remnant kidney rat: A possible role for transforming growth factor beta and hepatocyte growth factor

Nephron - Experimental Nephrology

Volumn 115, Issue 3, 2010, Pages

  De Beuf, Annelies ^a   D'Haese, Patrick C ^a   Verhulst, Anja ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Chronic renal failure; Erythropoietin; Fibrosis; Hepatocyte growth factor; Renoprotection; Transforming growth factor beta

Indexed keywords

COLLAGEN; HEMOGLOBIN; PROTEIN BCL 2; PROTEIN BCL X; RECOMBINANT ERYTHROPOIETIN; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; PROTEIN BAX; RECOMBINANT PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMATOPOIESIS; KIDNEY; KIDNEY FIBROSIS; KIDNEY FUNCTION; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; ANEMIA; ANIMAL; APOPTOSIS; BIOSYNTHESIS; BLOOD PRESSURE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; HUMAN; KIDNEY FAILURE, CHRONIC; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANEMIA; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FIBROSIS; HEMATINICS; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; NEPHRECTOMY; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA; ERYTHROPOIETIN; RECOMBINANT PROTEINS;

EID: 77951211332     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313830     Document Type: Article

References (49)

1. McClellan WM: The epidemic of renal disease - what drives it and what can be done? Nephrol Dial Transplant 2006; 21: 1461-1464.
2. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-1408. (Pubitemid 34655201)
3. Santoro A, Canova C: Anemia and erythropoietin treatment in chronic kidney diseases. Minerva Urol Nefrol 2005; 57: 23-31.
4. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619. (Pubitemid 29117643)
5. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63: 1908-1914.
6. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ: Anaemia in haemodialysis patients of five European countries: association with morbidity and mor - tality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132. (Pubitemid 38072623)
7. Engert A: Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 2005; 16: 1584-1595.
8. Macdougall IC: Erythropoietin and renal failure. Curr Hematol Rep 2003; 2: 459-464.
9. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
10. Tapolyai M, Kadomatsu S, Perera-Chong M: r.hu-erythropoietin (EPO) treatment of pre- ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003; 4: 3.
11. Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS: Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005; 21: 981-987.
12. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
13. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A: Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005; 3:CD003266.
14. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
15. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
16. Garcia DL, Anderson S, Rennke HG, Brenner BM: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 1988; 85: 6142-6146.
17. Lafferty HM, Garcia DL, Rennke HG, Troy JL, Anderson S, Brenner BM: Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension. J Am Soc Nephrol 1991; 1: 1180-1185.
18. Bellizzi V, Sabbatini M, Fuiano G, Sansone G, Magri P, Uccello F, Andreucci M, De Nicola L, Cianciaruso B: The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model. Nephrol Dial Transplant 1998; 13: 2210-2215.
19. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E, Guler F, Menne J, Haller H, Fliser D: Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012.
20. Kang DH, Park EY, Yu ES, Lee YS, Yoon KI: Renoprotective effect of erythropoietin (EPO): possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Kidney Int 2005; 67: 1683.
21. Deicher R, Horl WH: Differentiating factors between erythropoiesis- stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 2004; 64: 499-509
22. Smith WB, Dowell JA, Pratt RD: Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin Ther 2007; 29: 1368-1380.
23. Martin KJ: The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease. Clin Nephrol 2007; 68: 26-31.
24. Spinowitz BS, Pratt RD: Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 2006; 22: 2507-2513.
25. Kwan JT, Pratt RD: Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 2007; 23: 307-311.
26. Spinowitz BS: Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta. Haematologica 2008; 93: 761-764.
27. Hoesel W, Gross J, Moller R, Kanne B, Wessner A, Muller G, Muller A, Gromnica-Ihle E, Fromme M, Bischoff S, Haselbeck A: Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. J Immunol Methods 2004; 294: 101-110.
28. Gross J, Moller R, Henke W, Hoesel W: Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J Immunol Methods 2006; 313: 176-182.
29. Drueke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16(suppl 7):25-28.
30. Martin KJ: Epoetin delta in the management of renal anaemia: results of a 6-month study. Nephrol Dial Transplant 2007; 22: 3052-3054.
31. McDonald TP, Clift RE, Cottrell MB: Large, chronic doses of erythropoietin cause thrombocytopenia in mice. Blood 1992; 80: 352-358.
32. Rossert J, Fouqueray B, Boffa JJ: Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003; 14:S173-S177.
33. Simons JL, Provoost AP, Anderson S, Rennke HG, Troy JL, Brenner BM: Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 1994; 46: 396-404.
34. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, Sloand JA, Freedman BI, Williams WW Jr, Shadur CA: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-784.
35. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16: 307-312.
36. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996; 49: 666-678.
37. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
38. Coimbra TM, Carvalho J, Fattori A, Da Silva CG, Lachat JJ: Transforming growth factorbeta production during the development of renal fibrosis in rats with subtotal renal ablation. Int J Exp Pathol 1996; 77: 167-173.
39. Li J, Campanale NV, Liang RJ, Deane JA, Bertram JF, Ricardo SD: Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol 2006; 169: 1527-1540.
40. Matsumoto K, Nakamura T: Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001; 59: 2023-2038. (Pubitemid 32467594)
41. Mizuno S, Kurosawa T, Matsumoto K, Mizuno- Horikawa Y, Okamoto M, Nakamura T: Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 1998; 101: 1827-1834.
42. Mizuno S, Matsumoto K, Nakamura T: Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 2001; 59: 1304-1314.
43. Mizuno S, Nakamura T: Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol 2004; 286:F134-F143.
44. Kuiper EJ, Hughes JM, Van Geest RJ, Vogels IM, Goldschmeding R, Van Noorden CJ, Schlingemann RO, Klaassen I: Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest Ophthalmol Vis Sci 2007; 48: 4267-4276.
45. Rudnicki M, Perco P, Enrich J, Eder S, Heininger D, Bernthaler A, Wiesinger M, Sarkozi R, Noppert SJ, Schramek H, Mayer B, Oberbauer R, Mayer G: Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest 2009; 89: 337-346.
46. Tanaka T, Miyata T, Inagi R, Fujita T, Nangaku M: Hypoxia in renal disease with proteinuria and/or glomerular hypertension. Am J Pathol 2004; 165: 1979-1992.
47. Srisawat N, Manotham K, Eiam-Ong S, Katavetin P, Praditpornsilpa K, Eiam-Ong S: Erythropoietin and its non-erythropoietic derivative: do they ameliorate renal tubulointerstitial injury in ureteral obstruction? Int J Urol 2008; 15: 1011-1017.
48. Westenfelder C, Biddle DL, Baranowski RL: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820.
49. De Beuf A, Verhulst A, Helbert M, Spaepen G, De Broe ME, Ysebaert D, D'Haese P: Tubular erythropoietin receptor expression mediates erythropoietin-induced renoprotection. Open Hematol J 2009; 3: 1-10.